Adenosine
CLINICAL USE
paroxysmal supraventricular tachycardias
supraventricular tachycardias
DOSE IN NORMAL RENAL FUNCTION
Initially: 3 mg over 2 seconds with cardiac
monitoring followed, if necessary, by 6 mg
after 1–2 minutes and then by 12 mg after a
further 1–2 minutes
PHARMACOKINETICS
267.2
0
<5
No data
Unchanged
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
Not dialysed. Dose as in normal renal function
Not dialysed. Dose as in normal renal function
Unknown dialysability. Dose as in
normal renal function
Not dialysed. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
myocardial depression
of ventricular arrhythmias with
antipsychotics that prolong the QT
interval
depression
dipyridamole; therefore if use of adenosine
is essential, dosage should be reduced by a
factor of 4 (i.e. initial dosage of 0.5–1 mg)
potent inhibitors of adenosine
ADMINISTRATION
Reconstition
–
Route
IV
Rate of Administration
Rapid IV bolus (see dose)
Comments
Do not refrigerate
Administer into central vein, large
peripheral vein, or into an IV line. If IV
line used, follow dose by rapid sodium
chloride 0.9% flush
OTHER INFORMATION
involved in the degradation of exogenous
adenosine, so dose adjustments are not
required in hepatic or renal insufficiency
in conjunction with a beta-blocker
pain, dyspnoea, bronchospasm, nausea
and lightheadedness; the side effects are
short-lived